References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- Duchesne GM, Bolger JJ, Griffiths GO, et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000;47(2):379–388.
- Fossa SD, Hosbach G. Short-term moderate-dose pelvic radiotherapy of advanced bladder carcinoma. A questionnaire-based evaluation of its symptomatic effect. Acta Oncol. 1991;30(6):735–738.
- Srinivasan V, Brown CH, Turner AG. A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. Clin Oncol (R Coll Radiol)). 1994;6(1):11–13.
- Holmang S, Borghede G. Early complications and survival following short-term palliative radiotherapy in invasive bladder carcinoma. J Urol. 1996;155(1):100–102.
- McLaren DB, Morrey D, Mason MD. Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiother Oncol. 1997;43(2):171–174.
- Jose CC, Price A, Norman A, et al. Hypofractionated radiotherapy for patients with carcinoma of the bladder. Clin Oncol (R Coll Radiol). 1999;11(5):330–333.
- Kouloulias V, Tolia M, Kolliarakis N, et al. Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer. Int Braz j Urol. 2013;39(1):77–82.
- Lacarriere E, Smaali C, Benyoucef A, et al. The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery. Int Braz J Urol. 2013;39(6):808–816.
- Mery B, Falk AT, Assouline A, et al. Hypofractionated radiation therapy for treatment of bladder carcinoma in patients aged 90 years and more: a new paradigm to be explored? Int Urol Nephrol. 2015;47(7):1129–1134.
- Dirix P, Vingerhoedt S, Joniau S, et al. Hypofractionated palliative radiotherapy for bladder cancer. Support Care Cancer. 2016;24(1):181–186.
- Aljabab S, Cheung P, Dennis K, et al. Hemostatic radiotherapy in advanced bladder cancer: a single-institution experience. J Radiat Oncol. 2017;6(4):379–385.
- Ali A, Song YP, Mehta S, et al. Palliative radiation therapy in bladder cancer-importance of patient selection: a retrospective multicenter study. Int J Radiat Oncol Biol Phys. 2019;105(2):389–393.
- Wells GS, O’Connell D, et al. The Newcastle-Ottawa Scale for assessing the quality of non-randomized studies in meta-analyses. [cited 2021 Jan 19]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–413.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
- Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890:
- Aljabab S, Cheung P, Dennis K, et al. Hemostatic radiation therapy in advanced bladder cancer: a single-institution review. Int J Radiat Oncol Biol Phys. 2014;90(1):S696.
- Tey J, Soon YY, Cheo T, et al. Efficacy of palliative bladder radiotherapy for hematuria in advanced bladder cancer using contemporary radiotherapy techniques. In Vivo. 2019;33(6):2161–2167.
- Tey J, Soon YY, Koh WY, et al. Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(15):25797–25805.
- Fairchild A, Harris K, Barnes E, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008;26(24):4001–4011.